Isabelle Mahé on Reduced Dose Apixaban for Cancer-Associated VTE: API-CAT Trial Results
Isabelle Mahé, Head of Internal Medicine, Louis Mourier Hospital, APHP, Paris Cité University, reposted from Syed Saad Mahmood on LinkedIn:
”Thank you very much for the opportunity to discuss the results of the API-CAT Study adressing the extended anticoagulant treatment in patients with cancer associated thrombosis!”
Syed Saad Mahmood, System Director, Cardio-Oncology at Catholic Health, shared on LinkedIn:
”*St Francis Heart Center, NY CardioOncology Journal Club*
Dr. Isabelle Mahe (Université Paris Cité, France) joined us to discuss *API-CAT trial* evaluating whether among active cancer patients with venous thromboembolism, tx with a reduced dose oral anticoagulant is effective in preventing recurrent thromboembolic events and reduced bleeding”
Find more from Cardio-Oncology Journal Club.
Watch the full episode here.
Stay updated on the latest advancements in hemostasis research with Hemostasis Today.
-
Sep 17, 2026, 20:19Riten Kumar: Boston Children’s Hospital Ranked No. 1 in Seven Pediatric Specialties
-
Sep 17, 2026, 20:17Katrina Snow: Whole Blood or Component Therapy – Which Would You Choose?
-
Sep 17, 2026, 16:30Daria Camilli: Empowering Bleeding Disorder Advocacy Through Health Economics
-
Sep 17, 2026, 16:17Mehran Ghasemzadeh: Platelet NK Cell Crosstalk in Advanced Coronary Artery Disease
-
Sep 17, 2026, 16:16Barbara Adams Krolak: Do GLP-1s Affect Blood Clot Risk?
-
Sep 17, 2026, 15:46Heghine Khachatryan: Clinical Context at the Core of Thrombosis and Thrombophilia Management
-
Sep 17, 2026, 15:33Alexandros Makis: When Microcytic Anemia Has an Inherited Cause
-
Sep 17, 2026, 15:22α2-Antiplasmin Inhibition and the Future of Thrombolysis
-
Sep 17, 2026, 15:20Fatma M. Attia: Expanding the Evidence Base for Therapeutic Plasma Exchange Across Multiple Indications